[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.157.73. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Controversies
April 18, 2001

Industry Strongly Supports Continuing Medical Education

Author Affiliations

Author Affiliation: Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, DC.

 

Controversies Section Editor: Phil B. Fontanarosa, MD, Executive Deputy Editor.

JAMA. 2001;285(15):2012-2014. doi:10.1001/jama.285.15.2012

Just as it leads in biomedical innovation, the pharmaceutical industry is proud to play a leading role in sponsoring continuing medical education (CME) for physicians—an effort that serves the overriding mutual interest to ensure that patients receive the most up-to-date and appropriate care.

The accelerating pace of biomedical progress, in such fields as biochemistry, molecular biology, cell biology, immunology, genetics, and information technology, makes it more imperative than ever for physicians to stay abreast of the latest medical innovations and treatments. Particularly at a time when patients are increasingly demanding and receiving more health care information, the pharmaceutical industry and the medical profession are obligated to do all they can to ensure that physicians, the key prescribers of prescription medicines in the health care system, are thoroughly informed about the latest medical developments.

First Page Preview View Large
First page PDF preview
First page PDF preview
×